Association of Warfarin Use With CHADS2 Score in 441 Patients With Nonvalvular Atrial Fibrillation and No Contraindications to Warfarin

Preventive Cardiology, 05/07/2012

Desai HV et al. - There was no significant difference in use of warfarin between men and women and between whites and nonwhites.

Methods

  • The authors investigated the use of warfarin at hospital discharge in 557 consecutive patients, mean age 76 years, with nonvalvular atrial fibrillation (AF) at a university hospital.

Results

  • Of 557 patients with AF, 116 (21%) had contraindications to warfarin.
  • Of patients eligible for warfarin, warfarin was used in 8 of 30 patients (27%) with a CHADS2 score of 0, in 82 of 132 patients (62%) with a CHADS2 score of 1, in 121 of 175 patients (70%) with a CHADS2 score of 2, in 72 of 77 patients (94%) with a CHADS2 score of 3, and in 27 of 27 patients (100%) with a CHADS2 score of 4 to 6.
  • Warfarin was used in 123 of 168 patients (73%) older than 75 years, in 74 of 79 patients (94%) aged 65 to 75 years, and in 23 of 32 patients (72%) younger than 65 years.
  • Warfarin was used in 80 of 116 patients (69%) with a glomerular filtration rate <60 mL/min/1.73 m2 and in 140 of 163 patients (86%) with a glomerular filtration rate ≥60 mL/min/1.73 m2.

Print Article Summary Cat 2 CME Report